valuat freseniu medic reflect
overli pessimist outlook attract risk/reward investor
long believ kidney care industri one healthcar provid market support
durabl econom moat attract return capit post freseniu medic
support view firm carv uniqu competit posit underpin cost
advantag attain largest compani space industri convolut
reimburs structur back front-and-cent investor mind took closer look came away
confid outlook compani industri price concern weigh
heavili valuat given focu dialysi servic relianc market
freseniu fare bit better relev intern presenc domin dialysi
product busi help diversifi oper ultim believ critic product
servic provid freseniu ensur econom moat endur long
run follow recent weak investor opportun invest freseniu
roughli discount fair valu estim respect
think freseniu dug defens econom moat underpin cost advantag
built aggreg scale account treatment patient
nationwid busi secur market power think difficult displac
current market price impli near worst-cas outcom regard upcom vote proposit
california believ ballot measur unlik pass base-cas assumpt would call
roughli lower ebitda freseniu versu market-impli
expect suggest nearli respect page detail assumpt
dialysi servic one healthcar provid nich believ expos structur
growth driver give us ad confid forecast grow annual clip
past decad expect esrd popul expand roughli annual
freseniu trade meaning discount dcf-deriv fair valu estim
histor valuat multipl time time earn forecast
respect think investor would well-serv pick share narrow-moat
sizabl spread privat
price outlook becom clear
davita repres compel valu
sell-off creat opportun
analyst devic provid
share freseniu medic
conduct analyst govern
code ethics/cod conduct polici
secur trade polici equival
invest research polici inform
regard conflict interest pleas visit
page
page
page
page
page
page
page
page
dialysi remain moatworthi despit regulatori concern octob import disclosur end report
dialysi industri character host uniqu aspect think creat undu
concern investor least reimburs structur look almost noth like
area healthcar unfortun in-cent hemodialysi like remain
primari treatment modal patient suffer end-stag renal diseas esrd need
patient undergo treatment three time per week three four hour indefinit
receiv kidney transplant ensur esrd patient cost outlier nationwid result
congress author esrd program medicar classifi esrd diseas
categori univers cover medicar follow diagnosi irrespect age disabl
program maintain care coordin period patient commerci
insur plan remain primari payer kidney care need ensur medicar share
cost patient popul privat sector posit patient famili
dynam creat tough reimburs environ provid dialysi servic
medicar pay composit rate medicar payment advisori commiss medpac
estim provid roughli break-even profit servic provid shown exhibit
profit dispers individu facil level explain differ treatment
volum indic presenc scale advantag industri believ medicar
cover patient contribut littl overal industri profit pool
exhibit medicar reimburs rate allow break-even margin
medicar margin weaken recent year net payment rate kept pace inflat
page
page
page
page
page
page
page
page
dialysi remain moatworthi despit regulatori concern octob import disclosur end report
effect medicar reimburs polici forc industri profit levi patient maintain
commerci plan primari payer month follow initi diagnosi estim
commerci insur popul make vast minor overal dialysi patient
treat exhibit use data dialysi facil report aggreg
center medicar medicaid servic break patient report
primari insur coverag type carrier number broadli line metric report
freseniu import note rest industri treat similar
patient mix well
exhibit mix primari insur coverag patient treat
provid requir treat remain patient close break-even reimburs
rate success necessit build scale effect negoti privat payer argu
freseniu success pursu strategi exhibit show
two firm account total facil patient treat market
result long-term trend toward consolid expect continu illustr
exhibit help hand larger acquisit need attain scale ensur
number provid fall independ smaller region chain categori steadili
erod growth freseniu year
page
page
page
page
page
page
page
page
dialysi remain moatworthi despit regulatori concern octob import disclosur end report
exhibit market share measur proport total dialysi clinic
page
page
page
page
page
page
page
page
dialysi remain moatworthi despit regulatori concern octob import disclosur end report
end result industri domin two nation chain enough negoti leverag
wrestl favor price commerci insur allow sustain excess firm-wide
return capit chang made reimburs methodolog fortifi
freseniu domin competit posit view combin label chang made key
renal drug transit bundl payment rate dramat lower util
in-cent administ pharmaceut concurr dialysi therapi result rebas
bundl payment rate approxim five year end led roughli flat
reimburs environ illustr period rate cut squar rearview
mirror net updat propos consist expect normal
oper environ industri come year
believ like polici chang perman lower industrywid return capit
also encourag continu market consolid cost advantag afford
freseniu allow continu valu creation suggest return spread illustr
exhibit said doubt smaller provid found similar success maintain reason
level econom return underpin help explain dialysi industri evolv
time oligopolist market structur defin dialysi today
exhibit top freseniu bottom consist gener attract return capit despit industri headwind
page
page
page
page
page
page
page
page
dialysi remain moatworthi despit regulatori concern octob import disclosur end report
sizabl spread privat public payer rate draw undu scrutini
juli issu propos updat medicar esrd prospect payment would
peg outpati dialysi base reimburs rate per treatment calendar year
posit net improv last year per treatment rate payment
continu fall short medpac estim cost treat averag medicar patient
add-on outlier payment region cost adjust like improv metric somewhat data
dialysi cost report suggest averag cost fall near per treatment notabl metric
correl neg number treatment conduct year per facil suggest
meaning advantag scale present use data back estim privat payer
rate help demonstr level negoti leverag present freseniu use
exampl exhibit given compani granular level disclosur sign
point similar dynam freseniu
given domin presenc within dialysi servic commerci insur choic
contract freseniu bring in-network craft region insur
product give provid firm upper hand negoti reimburs rate
otherwis power payer commerci reimburs rate typic greater paid
area healthcar averag price diverg within dialysi particularli
tend see dynam result incent commerci insur get esrd patient
book increasingli difficult proposit follow passag patient protect
afford act hand provid incent maxim
commerci patient mix order subsid grow proport medicar patient treat
break-even rate result hand recur theme believ weigh
valuat freseniu past two three year
 dialysi servicesrevenuepatientsestim treatmentsimpli revenu per page
page
page
page
page
page
page
page
dialysi remain moatworthi despit regulatori concern octob import disclosur end report
charit assist american kidney fund
begin alleg emerg dialysi provid use third-parti charit
assist payment primarili american kidney fund akf steer medicaid-elig
patient toward aca-compli plan individu insur marketplac number
small roughli fewer total patient treat profit impact given schism
public privat reimburs level legal risk associ firm relationship
akf main sourc risk investor manag estim impact would annual
roughli ebitda segment prior cost offset contribut
firm limit growth profit past year freseniu absolut number patient
receiv patient assist enrol individu insur suggest lower
less materi risk firm overal busi ultim suspend support
akf applic patient medicaid coverag look enrol aca-compli
plan uncertainti associ potenti polici chang larg dissip
chang administr januari continu keep eye policymak
initi look revisit issu
initi look lower industri profit local legisl polici chang
thu far legisl grassroot initi look curb dialysi industri profit gain
support initi expect particularli california surpris passag senat
state legislatur spark sell-off share freseniu investor
fear state-level policymak could spread broadli gov jerri brown veto legisl
upcom vote proposit remain acut risk dialysi servic provid state
look effect cap reimburs rate specif small number commerci
insur patient receiv third-parti financi assist prop hand wider-
reach attempt cap dialysi facil price across treat patient state
initi becom contest battleground would anticip
begin year contribut campaign pace set record level spend
one side statewid ballot measur addit given brown veto bill cite need
narrow solut ensur patient access feel prop face hurdl
implement current written pass factor leav us think passag unlik
ran scenario analysi handicap differ outcom might mean investor prop
defin bucket allow cost clinic would allow price equival
cost current propos direct patient care cost includ salari wage benefit
nonmanageri clinic staff train develop cost laboratori test pharmaceut
medic suppli facil cost includ rent mainten util depreci
amort qualifi allow cost cost associ manageri staff interest
expens current fall definit california particularli import state
given approxim share statewid facil fall near exhibit estim
potenti ebitda impact compani sensit across proport gener administr
expens might ultim categor allow
page
page
page
page
page
page
page
page
dialysi remain moatworthi despit regulatori concern octob import disclosur end report
cost offset oper chang freseniu would abl continu
oper prop go full effect import note howev roughli
statewid facil affili top two firm would face higher hurdl continu
profit estim facil would unprofit ballot initi pass
would like restrict patient access support skeptic
exhibit risk appear manag prop go effect
ultim view rang outcom manag estim reflect like risk
mitig stem oper chang cost offset potenti ebitda shortfal limit
mid-single-digit rang comfort current valuat assumpt
hamm kellih russo assess impact california proposit berkeley research group juli
prop impact analysi dialysi dialysi dialysi allow revenu estim allow price revenu expos pre-tax dialysi fair valu costsunallow costsundefin page
page
page
page
page
page
page
page
dialysi remain moatworthi despit regulatori concern octob import disclosur end report
freseniu would even less affect given divers oper global lower-than-averag
share within california estim freseniu oper roughli facil state
would suggest impact closer firm-wide ebitda similar assumpt scenario
freseniu assum profit reduct equal half amount illustr reflect
firm proport lower exposur state
valuat work compani incorpor potenti headwind rule
base-cas model given low likelihood assign prop pass nov elect
strictli enforc current written said think current market price provid
attract margin safeti long-term investor isol potenti valuat scenario capit
reduct after-tax cash flow perpetu base- bull- bear-cas outlook risk
intrins valu busi think market current discount scenario
believ pessimist unlik els equal market-impli expect seem suggest
investor anticip near worst-cas outcom view creat attract
risk/reward profil compani highlight bear-cas assumpt tabl
result fair valu estim would line current market price
volum trend help support growth price outlook becom clear
follow multi-year period rel flat reimburs updat rate propos
come relief mani oper industri without broader comprehens
reorgan industri structur dichotomi commerci govern payment
rate unlik materi chang view howev follow final payment bundl rebas
adjust expect return consist reimburs increas help
off-set oper cost inflat outstrip total price improv recent year
use quantifi metric exhibit given compani granular disclosur
believ freseniu similarli affect
exhibit per-treat inflat surpass price updat recent year
page
page
page
page
page
page
page
page
dialysi remain moatworthi despit regulatori concern octob import disclosur end report
volum side equat esrd unfortun pois growth market year
come esrd patient popul grown compound annual rate roughli
past decad spur grow preval diabet hypertens among adult
popul two disord far common lead caus kidney diseas cite
esrd patient primari diagnosi nearli two third preval case
appear occurr condit set improv time soon either diagnos
undiagnos diabet expect grow popul nearli
estim domest esrd popul continu grow clip come year
expect freseniu gain modest share time illustr exhibit
magnitud consist volum growth rel rare among healthcar provid market
think long attract uniqu aspect dialysi industri investor
combin modest blend price growth expect overal market grow annual
rate forecast horizon
esrd popul expand decad freseniu consist report above-market growth
think dialysi industri uniqu consist econom profit gener compar
healthcar provid acut care underpin belief
freseniu develop durabl econom moat scale-deriv advantag allow
firm wield market power negoti privat payer oper facil
effici smaller peer
rowley bezold arikan byrn krohe diabet insight yesterday today futur trend popul health
page
page
page
page
page
page
page
page
dialysi remain moatworthi despit regulatori concern octob import disclosur end report
wherea much acut care provid space highli fragment nation level
market leader estim account roughli total admiss dialysi highli
concentr freseniu combin account roughli treatment facil
patient treat nationwid year forecast assum market continu consolid
time uniqu reimburs structur present dialysi servic necessit market
structur view underpin strength price firm abl extract
cost side equat think freseniu abil obtain market-lead
profit strong excess return capit suggest cost advantag like present
industri sit atop rel variabl cost structur think scale-deriv advantag procur
allow better input price subscal peer labor gener administr medic
suppli combin drug suppli repres bulk industrywid cost per
treatment illustr exhibit think bucket lend well scale-deriv cost
advantag remain core underpin narrow-moat rate firm view
support medpac analysi identifi statist signific neg correl
coeffici total treatment conduct facil facil cost per treatment
impli meaning benefit scale
exhibit dialysi treatment
page
page
page
page
page
page
page
page
dialysi remain moatworthi despit regulatori concern octob import disclosur end report
addit view abil larg dialysi chain oper facil effici
smaller entiti compel long-term advantag measur either capac util
total treatment conduct per facil year oper metric report
freseniu stand well ahead peer illustr anoth way exhibit stratifi medicar profit
facil quintil rank treatment conduct per year highlight magnitud variabl
exist highest lowest volum oper effici oper report
medicar margin averag approxim percentag point better lowest quintil
facil believ continu critic long-term success entiti
exhibit profit correl posit metric facil effici
highest volum facil report industry-lead medicar margin help high capac util leverag
notabl appear large-scal dialysi provid sacrif qualiti sake
reduc cost measur system govern qualiti rate dialysi facil dialysi
facil compar program esrd qualiti incent program star program assign
rate worst best star base facil score across varieti health static
compar nation averag qualiti program directli tie reimburs level
facil score across clinic safeti report metric payment penalti levi
under-perform freseniu oper disproportion share high-
perform facil methodolog under-repres among group
facil face payment reduct rate categori exhibit
show distribut facil rank penalti rate star rate recent
page
page
page
page
exhibit freseniu account major high-perform facil variou qualiti metric
page
freseniu face limit headwind penalti margin exposur rate facil
page
page
page
dialysi remain moatworthi despit regulatori concern octob import disclosur end report
davita repres compel valu current market price
sinc materi underperform compar peer freseniu
 healthcar sector market whole reflect exhibit think larg
stem compani concentr exposur payer dynam explor throughout
report investor comfort diversifi effect freseniu broader
intern footprint domin product busi help dampen direct exposur
reimburs level gener nearli revenu oper compar
roughli freseniu said think discount unwarr given
attract normal growth profil expect oper improv follow divest
davita medic group dmg slate late
exhibit share price perform lag dramat past year
page
page
page
page
page
page
page
page
dialysi remain moatworthi despit regulatori concern octob import disclosur end report
dmg noth drag overal compani perenni distract
manag investor alik think firm remain segment pois continu
strength estim firm moatworthi dialysi servic busi continu grow
marketlik rate addit forecast segment ebitda margin remain larg steadi
time averag come five-year period view bigger
inflect like occur firm fledgl intern dialysi servic busi
report more-or-less break-even profit past year forecast
busi grow moati intern franchis akin freseniu global oper
believ increment contributor profit gain attent deserv
follow dmg divestitur expect firm ancillari servic strateg initi segment
hous intern dialysi servic along pharmaci diseas manag vascular
access servic among thing add nearli million increment ebitda
oper consist mid-single-digit margin like addit opportun beyond
improv shown exhibit intern dialysi busi gain scale necessari
exhibit without distract dmg think intern oper improv
compani foray broader healthcar manag dmg acquisit like
leav investor rel cautiou relat manag on-going capit alloc strategi
said impress billion price tag abl get busi
encourag manag earmark cash infus debt reduct share
repurchas come year happi see manag priorit rightsiz firm pro
forma balanc sheet buy stock near current price think value-enhanc
dialysi remain moatworthi despit regulatori concern octob import disclosur end report
